Russell Investments Group, Ltd. Supernus Pharmaceuticals, Inc. Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 109,547 shares of SUPN stock, worth $3.96 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

109,547

Previous 100,262 9.26%

Holding current value

$3.96 Million

Previous $2.68 Million 27.33%

% of portfolio

0.01%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$25.77 - $35.16 $239,274 - $326,460	9,285 Added 9.26%	109,547 $3.42 Million
Q2 2024 Aug 08, 2024	BUY	$25.99 - $33.85 $59,101 - $76,974	2,274 Added 2.32%	100,262 $2.68 Million
Q1 2024 May 08, 2024	BUY	$27.11 - $35.17 $1.79 Million - $2.32 Million	65,880 Added 205.18%	97,988 $3.34 Million
Q4 2023 Feb 05, 2024	BUY	$22.72 - $29.68 $50,256 - $65,652	2,212 Added 7.4%	32,108 $929,000
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $566,977 - $676,794	-20,565 Reduced 40.75%	29,896 $824,000
Q2 2023 Aug 10, 2023	BUY	$29.91 - $38.73 $1,256 - $1,626	42 Added 0.08%	50,461 $1.52 Million
Q1 2023 May 09, 2023	BUY	$34.93 - $42.03 $527,058 - $634,190	15,089 Added 42.71%	50,419 $1.83 Million
Q3 2022 Nov 04, 2022	BUY	$28.79 - $35.41 $592,786 - $729,091	20,590 Added 139.69%	35,330 $1.2 Million
Q1 2022 May 05, 2022	SELL	$28.51 - $32.9 $273,325 - $315,412	-9,587 Reduced 39.41%	14,740 $476,000
Q4 2021 Jan 21, 2022	BUY	$26.37 - $34.22 $252,809 - $328,067	9,587 Added 65.04%	24,327 $708,000
Q3 2021 Nov 08, 2021	SELL	$23.54 - $31.39 $100,892 - $134,537	-4,286 Reduced 22.53%	14,740 $393,000
Q2 2021 Aug 04, 2021	SELL	$26.72 - $33.19 $1.51 Million - $1.88 Million	-56,675 Reduced 74.87%	19,026 $584,000
Q1 2021 May 10, 2021	SELL	$24.15 - $31.45 $932,721 - $1.21 Million	-38,622 Reduced 33.78%	75,701 $1.98 Million
Q4 2020 Feb 08, 2021	SELL	$17.7 - $25.81 $1.18 Million - $1.73 Million	-66,941 Reduced 36.93%	114,323 $2.88 Million
Q3 2020 Nov 09, 2020	SELL	$20.2 - $25.05 $2.18 Million - $2.7 Million	-107,782 Reduced 37.29%	181,264 $3.78 Million
Q2 2020 Aug 05, 2020	BUY	$17.09 - $24.89 $2.74 Million - $3.99 Million	160,345 Added 124.59%	289,046 $6.81 Million
Q1 2020 May 06, 2020	BUY	$14.45 - $24.69 $358,634 - $612,781	24,819 Added 23.89%	128,701 $2.23 Million
Q4 2019 Jan 29, 2020	SELL	$19.93 - $29.13 $1.57 Million - $2.3 Million	-78,828 Reduced 43.14%	103,882 $2.43 Million
Q3 2019 Nov 01, 2019	SELL	$25.47 - $33.37 $957,366 - $1.25 Million	-37,588 Reduced 17.06%	182,710 $5.02 Million
Q2 2019 Aug 09, 2019	SELL	$29.96 - $38.87 $552,732 - $717,112	-18,449 Reduced 7.73%	220,298 $7.06 Million
Q1 2019 May 13, 2019	SELL	$32.77 - $41.99 $3.82 Million - $4.89 Million	-116,560 Reduced 32.81%	238,747 $8.19 Million
Q4 2018 Feb 11, 2019	SELL	$30.84 - $49.51 $1.02 Million - $1.64 Million	-33,166 Reduced 8.54%	355,307 $11.6 Million
Q3 2018 Oct 26, 2018	SELL	$42.7 - $56.55 $1.86 Million - $2.46 Million	-43,551 Reduced 10.08%	388,473 $19.5 Million
Q2 2018 Aug 08, 2018	SELL	$44.1 - $59.85 $22.6 Million - $30.7 Million	-512,362 Reduced 54.25%	432,024 $25.5 Million
Q1 2018 May 11, 2018	BUY	$37.15 - $46.9 $1.97 Million - $2.49 Million	53,026 Added 5.95%	944,386 $43.3 Million
Q4 2017 Feb 06, 2018	BUY	$36.4 - $42.6 $2 Million - $2.34 Million	55,020 Added 6.58%	891,360 $36.4 Million
Q3 2017 Nov 07, 2017	BUY	$36.75 - $49.65 $30.7 Million - $41.5 Million	836,340	836,340 $33.5 Million

Others Institutions Holding SUPN

# of Institutions

279

Shares Held

61M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Supernus Pharmaceuticals, Inc. Transaction History